Enzalutamide performs well in metastatic hormone-sensitive prostate cancer
- 5 August 2022
- conference paper
- conference paper
- Published by Medicom Medische Uitgeverij BV in Medicom Conference Report ASCO 2022
Abstract
No abstract availableThis publication has 1 reference indexed in Scilit:
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerThe New England Journal of Medicine, 2019